BiotechTube
Home/Stemline Therapeutics/Ivan Bergstein, MD
IB

Ivan Bergstein, MD

Chief Executive Officer, President and Founder

Stemline Therapeutics

Therapeutic Areas

OncologyHematologic OncologyBreast Cancer

Stemline Therapeutics Pipeline

DrugIndicationPhase
ELZONRIS (tagraxofusp)Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Approved
ORSERDU (elacestrant)ER+/HER2-, ESR1-mutated Advanced/Metastatic Breast CancerApproved